Clinical Guidance

Switching GLP-1 Medications: How Physicians Manage the Transition

Whether the trigger is a formulary change, a plateau, side effects, or price, moving between GLP-1 medications is routine clinical work. What it is not is a self-service swap: doses do not translate one-to-one between molecules, and the safe transition is a physician's mapping of dose, timing, and expectations.

Reviewed by board-certified physicians · Published 2026-08-28 · Updated 2026-08-28 · 8 min read

Key facts

  • Milligrams do not carry meaning across molecules: semaglutide and tirzepatide doses are not interchangeable numbers.
  • Switching within the same molecule (compounded tirzepatide to Zepbound®, injection to oral semaglutide) is a format mapping. Switching across molecules is a clinical re-titration decision.
  • Physicians commonly time the first dose of the new medication roughly one dosing interval after the last dose of the old one, adjusted to the situation.
  • Some side effect resurgence during a switch is common and usually transient.
  • Most switches do not restart at the lowest dose, but the landing dose is a judgment call, not a chart lookup.

Why is there no official conversion chart?

Because the manufacturers never studied one. Each medication's label defines its own titration from its own starting dose; none defines an entry point for arriving mid-treatment from a different drug. Every conversion table circulating online is somebody's synthesis, informed at best by payer equivalence tables and clinical experience, not by a trial. Useful context for a physician; hazardous as a self-service instruction.

The absence of a chart is not an absence of knowledge. Physicians move patients between these medications constantly and the principles are settled. The point is that the landing dose is chosen for you, factoring your current dose, how long you have held it, tolerance history, and why you are switching at all.

What does a same-molecule switch look like?

Moving between formats of the same molecule is the gentle case. Compounded tirzepatide to Zepbound®, or the reverse, keeps the milligram language, and the physician's work is mostly format translation: pens dose in fixed steps while vials are drawn in units, so the practical instructions change even when the milligrams do not. The concentration printed on a compounded vial is per vial, not per dose, which is where self-managed switches go wrong; our vial and syringe guide covers the arithmetic.

Injectable semaglutide to the oral tablet has published correspondence guidance from its manufacturer, plus the tablet's empty-stomach routine to adopt. In all same-molecule cases, expect the possibility of a brief adjustment period and not much more.

What about switching between semaglutide and tirzepatide?

This is the re-titration case. The physician picks an entry dose of the new molecule that respects your incretin experience, typically not the raw beginner dose after months of established treatment, but rarely a straight top-tier entry either, and then titrates from there. Expect the first weeks to feel like a mild echo of your original start: appetite effects shift, and gastrointestinal side effects can resurface briefly around the change.

Going the other direction, tirzepatide to semaglutide, usually driven by coverage, follows the same logic with one added expectation to manage: population averages differ between the molecules, so the physician may also reset the trajectory conversation, not just the dose.

3/mo CHROMA23+ Membership unlocks it at one clear price, medication priced separately and always shown.

Start the free assessment · Explore weight loss treatments

How is the timing between the last old dose and the first new one handled?

For the weekly injectables, the common approach is to start the new medication about when the next dose of the old one would have been due, roughly a week after the last shot, so exposure hands off without stacking. Longer gaps sometimes make sense after side effect trouble; short overlaps are avoided. Daily pills entering or leaving the picture shift the arithmetic, which is exactly the kind of detail the prescribing physician specifies rather than a rule you improvise.

If a supply gap forced your switch and weeks have already passed, say so. After a long enough gap the safest plan can look more like a restart than a handoff, and pretending continuity helps nobody.

Will I gain weight or lose progress during the switch?

Over a competently managed transition of days to weeks, meaningful regain is uncommon. Appetite can feel louder in the gap and the first weeks on the new molecule may feel different rather than worse, stronger for some, gentler for others. Give the new medication a full titration before judging it; a switch evaluated at week two is a coin flip narrated with feelings.

The forced-switch scenario, where a pharmacy benefit manager changes its preferred brand and your next fill changes with it, deserves the same discipline. It is an administrative event, but the transition through it is still clinical. Loop in the prescribing physician rather than simply filling the new box and continuing your old numbers, and if the coverage picture is the real problem, our denial options guide maps the alternatives.

Frequently asked questions

Do side effects reset completely when I switch?

Usually not completely. Most people experience a milder, shorter echo of their original adjustment period rather than a full rerun, because the incretin system is already adapted. Tolerance is molecule-specific enough that some people genuinely do better on the new medication, in either direction.

I switched from a compounded vial to pens. Why does my dose number look different?

Pens are labeled by per-dose milligrams in fixed steps; vials are labeled by total concentration and drawn in syringe units. Same language, different grammar. Confirm your per-dose milligrams with the physician and pharmacy label, then confirm what that means in units or clicks for your specific product.

How long should I wait between the last semaglutide shot and the first tirzepatide shot?

The common clinical pattern lands the first new dose around the time the next old dose would have been due, adjusted for your situation. The exact timing is set by the prescribing physician; there is no universal number worth self-applying.

Can CHROMA23® manage a switch from another provider?

Yes, that is a routine arrival path. Bring your current medication, dose, last-dose date, and how the treatment has felt. A board-certified physician reviews it through the free assessment and maps the transition if treatment is appropriate, with every cost shown before anything is prescribed.

About CHROMA23®

CHROMA23® is a clinical weight loss platform built on prescription protocols: injectables, oral medicine, and the protocols that come next, under one 3 membership. Every prescription decision is made by an independent, board-certified physician licensed in the patient's state, and every medication is dispensed by a state-licensed pharmacy. The assessment is free. The membership is 3. The medicine is real. The physician is real.

Sources

  1. Zepbound® full prescribing information: dosing and titration
  2. Wegovy® full prescribing information: dosing and titration
  3. Barenbaum et al.: real-world outcomes in patients switched from semaglutide to tirzepatide (Obesity, 2026)
  4. MassHealth Pharmacy Facts: management of anti-obesity agents, incl. dose equivalency tables (March 2026)
  5. SURMOUNT-5 head-to-head trial (NEJM 2025)

Keep reading

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Always consult a board-certified physician about your individual situation. Figures from named clinical trials describe study populations; individual results vary and are not typical.

All articles